Please assess the completion status of the following clinical trial:

Trial Title: Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component~* Patients must be candidates for platinum based chemotherapy and previously untreated~* Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy~* Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue block or a minimum of 15 slides~* ECOG PS 0-1~* Adequate hematological, renal, and liver function~Key Exclusion Criteria:~* Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors~* Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior immunotherapy with IL 2, IFN α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways~* Patients for whom, in the opinion of the Investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting.~* Cancer for which intraperitoneal cytotoxic chemotherapy is planned~* Active autoimmune disease (some exceptions include diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Chemotherapy followed by observation
- Arm B (Type: EXPERIMENTAL): Chemotherapy followed by avelumab in maintenance
- Arm C (Type: EXPERIMENTAL): Chemotherapy in combination with avelumab followed by avelumab in maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).